Coronavirus: Commission signs contract for the supply of a monoclonal antibody treatment

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


The Commission has signed a joint procurement framework contract with the pharmaceutical company Eli Lilly for the supply of a monoclonal antibody treatment for coronavirus patients. This marks the latest development in this first portfolio of five promising therapeutics announced by the Commission under the EU COVID-19 Therapeutics Strategy in June 2021. The medicine is currently under rolling review by the European Medicines Agency. 18 Member States have signed up to the joint procurement for the purchase of up to 220,000 treatments.

Stella Kyriakides, Commissioner for Health and Food Safety, said: “Over 73% of the EU adult population is now fully vaccinated, and this rate will still increase. But vaccines cannot be our only response to COVID-19. People still continue to be infected and fall ill. We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics. With today’s signature, we conclude our third procurement and deliver on our commitment under the EU Therapeutics Strategy to facilitate access to state-of-the-art medicines for COVID-19 patients.”

While vaccination remains the strongest asset both against the virus and its variants, therapeutics play a critical role in the COVID-19 response. They help to save lives, speed up recovery time, reduce the length of hospitalisation and ultimately ease the burden of health care systems.

The product from Eli Lilly is a combination of two monoclonal antibodies (bamlanivimab and etesevimab) for the treatment of coronavirus patients who do not require oxygen but are at high risk of severe COVID-19. Monoclonal antibodies are proteins conceived in the laboratory that mimic the immune system’s ability to fight the coronavirus. They fuse to the spike protein and thus block the virus’s attachment to the human cells.

Under the EU Joint Procurement Agreement, the European Commission has concluded until now nearly 200 contracts for different medical countermeasures with a cumulative value of over €12 billion. Under the joint procurement framework contract concluded with Eli Lilly, Member States can purchase the combination product bamlanivimab and etesevimab if and when needed, once it has received either a conditional marketing authorisation at EU level from the European Medicines Agency or an emergency use authorisation in the Member State concerned.

Background

Today’s joint procurement contract follows the contract signed with Roche for the product REGN-COV2, a combination of Casirivimab and Imdevimab, on 31 March 2021 and the contract with Glaxo Smith Kline on 27 July 2021 for the supply of sotrovimab (VIR-7831), developed in collaboration with VIR biotechnology.

The EU Strategy on COVID-19 Therapeutics, adopted on 6 May 2021, aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. It will also coordinate, scale-up and ensure that the EU acts together in ensuring access to therapeutics via joint procurements.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe’s health systems. Focusing on the treatment of patients with COVID-19, the Strategy works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

On 29 June 2021, the strategy delivered its first outcome, with the announcement of five candidate therapeutics that could soon be available to treat patients across the EU. The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the strategy, provided the final data demonstrate their safety, quality and efficacy.

Global cooperation on therapeutics is crucial and a key component of our strategy. The Commission is committed to working together with international partners on COVID-19 therapeutics and make them available globally. The Commission is also exploring how to support the enabling environment for manufacturing health products, while strengthening research capacity in partner countries around the globe.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Why the foundations of the modern world are costing the earth

World Cancer Day: Early cervical cancer diagnosis could save lives of over 300,000 women

Covid-19 crisis shows supply chains need to embrace new technologies

What is adversarial artificial intelligence and why does it matter?

MEPs want to ensure sufficient funding for Connecting Europe’s future

Two out of every five American couples now meet online

Trade defence report: restoring the level playing field for European producers

Peace operations benefit from improved cooperation between the UN and troop-providing countries, says peacekeeping chief

Switzerland has the most highly skilled workers in the world. This is why

Infringement – Commission takes Italy to Court for its incomplete regime of access to genetic resources

Capital Markets Union: Making it easier for insurers to invest in the real economy

Venezuela: ‘A worrying destabilizing factor in the region’, Bachelet tells Human Rights Council

How cocoa farming can help stop deforestation

Inaction over climate emergency ‘not an option’ says UN Assembly chief

A Year in China

Drug laws must be amended to ‘combat racial discrimination’, UN experts say

What UK and EU risk if Brexit “wins” these elections

€200 million to promote European agri-food products in and outside the EU

Palliative care and Universal Health Coverage: how to advocate for the inclusion of palliative care in UHC

Eurozone in trouble after Nicosia’s ‘no’

Questions and Answers on the EU Digital Covid Certificate

The Shifting Rhythms of Harmonious China: Ancient, Modern & Eternal

Obsolete tech is clogging up global trade. Here’s how to unblock it

Rebuilding after COVID: The challenge is digital

UNIDO promotes post-harvest excellence for mangoes in the Mekong River Delta of Viet Nam

Palliative Care: a human right

Collective action now, the only way to meet global challenges, Guterres reaffirms in annual report

NHS: A great healthcare system but how accessible is it to migrants?

Sub10 Systems @ MWC14: Bridging the Ethernet of the Future

Citizens to be the cornerstone of the Conference on the Future of Europe

Lessons learnt, unlearnt or re-learnt? Analyzing the third wave of COVID-19

The post-pandemic future of work – according to 3,000 CEOs from around the world

Growing a new coral reef in a fraction of the time with a fragment of the coral

Poland: €676 million worth of EU investments in better rails and roads

Main results of EU-Japan summit: Tokyo, 17/07/2018

Ocean life faces ‘onslaught of threats’ from human activity, but tools exist to save it

270 million people are migrants, who send home a staggering $689 billion

Human rights: breaches in Iran, Saudi Arabia and Sudan

Climate action ‘both a priority and a driver of the decade’: Guterres

Coronavirus Global Response: WHO and Commission launch the Facilitation Council to strengthen global collaboration

As tech disrupts our jobs, it’s not too late to turn pain into gain

State aid: Commission approves €2 billion Italian guarantee scheme to support trade credit insurance market in the context of the coronavirus outbreak

Teachers launch a free ebook to help children cope with the pandemic

COVID-19 has been a setback for women. Gender-responsive policies can stem the losses

How COVID-19 vaccine efforts could help defeat other diseases

European financial values on the rise

Human Rights breaches in Iran, Kazakhstan and Guatemala

COVID-19: EU helps to deliver vaccines to Moldova and medical items to Montenegro and North Macedonia

UN Human Rights chief urges Venezuela to halt grave rights violations

West Bank: ‘imminent’ demolition of Palestinian village could be ‘war crime’ – ICC Prosecutor

Cities will lead the electric transport revolution. Here’s why

An alternative view of Globalization 4.0, and how to get there

This is what Belgium’s traffic-choked capital is doing about emissions

Closing the gaps in accelerating women’s rights: the role of medical students

Companies ‘failing’ to address offline harm incited by online hate: UN expert

Why the 33,000 staff European Commission did not have a real contingency plan for the refugee crisis?

‘Maintain calm’ and ‘exercise patience’ UN envoy urges, as Nigeria heads to polls

This UK footballer just won free school meals for kids in the summer holidays

6 stages for fostering and harnessing imagination in companies

‘We will not give up on looking for peace for South Sudan’: UN deputy chief

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: